PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Wall St ends lower for the day and week as chip selloff broadens
PhaseBio Pharmaceuticals Inc. (PHAS) PT Lowered to $16 at Needham & Company
May 14, 2021 1:51 PM EDTNeedham & Company analyst Chad Messer lowered the price target on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) to $16.00 (from $19.00) while maintaining a Buy rating.
The analyst commenetd, "In March, PhaseBio announced enrollment in the Phase III REVERSE-IT trial was running ahead of schedule, enrolling... More
